All Stories

  1. Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy

    Article • Neuropharmacology, March 2026, Elsevier

    Professor Javier Fernández-Ruiz

  2. Development of cannabinoid-based therapies for Parkinson’s disease: emphasis on targeting cannabinoid receptors as CB2, PPAR-γ and GPR55 receptors

    Article • Molecular Neurodegeneration Advances, January 2026, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  3. Defining the Intestinal eCBome and Oxylipin Signaling Systems in a TDP‐43 Mouse Model of Frontotemporal Dementia

    Article • The FASEB Journal, January 2026, Wiley

    Professor Javier Fernández-Ruiz

  4. Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB2 receptor activation in experimental ALS in male mice

    Article • Cell Communication and Signaling, October 2025, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  5. Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis

    Article • Biomedicine & Pharmacotherapy, August 2025, Elsevier

    Professor Javier Fernández-Ruiz

  6. Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (−) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives

    Article • European Journal of Medicinal Chemistry Reports, August 2025, Elsevier

    Professor Javier Fernández-Ruiz

  7. Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery

    Article • Toxicologic Pathology, May 2025, SAGE Publications

    Professor Javier Fernández-Ruiz

  8. Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome

    Article • Brain Behavior & Immunity - Health, March 2025, Elsevier

    Professor Javier Fernández-Ruiz

  9. Ageing, Neurodegeneration and the Endocannabinoid System

    Article • January 2025, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  10. Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays

    Article • January 2025, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  11. Neurodegeneration and the endocannabinoid system: Toward the development of cannabinoid-based therapies for Parkinson's disease, amyotrophic lateral sclerosis and spinocerebellar ataxias

    Article • January 2025, Elsevier

    Professor Javier Fernández-Ruiz

  12. Mouse Models of Amyotrophic Lateral Sclerosis

    Article • December 2024, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  13. Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

    Article • Behavioral and Brain Functions, November 2024, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  14. Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

    Article • Antioxidants, September 2024, MDPI AG

    Professor Javier Fernández-Ruiz

  15. Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche’s Endocannabinoid System Projects

    Article • CHIMIA International Journal for Chemistry, August 2024, Swiss Chemical Society

    Dr Rainer E Martin, Professor Javier Fernández-Ruiz

  16. Preclinical Assessment of a Cannabinoid CB2 Receptor Antagonist in a Murine Model of Cerebral Malaria

    Article • Journal of Trial and Error, August 2024, JOTE Publishers

    Professor Javier Fernández-Ruiz

  17. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice

    Article • Biomedicine & Pharmacotherapy, May 2024, Elsevier

    Professor Javier Fernández-Ruiz

  18. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline

    Article • British Journal of Pharmacology, January 2024, Wiley

    Professor Javier Fernández-Ruiz

  19. Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

    Article • Neuropharmacology, October 2023, Elsevier

    Professor Javier Fernández-Ruiz

  20. The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

    Article • Brain Sciences, August 2023, MDPI AG

    Professor Javier Fernández-Ruiz

  21. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

    Article • Journal of Neuroinflammation, May 2023, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  22. Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure–Activity Relationship

    Article • ACS Medicinal Chemistry Letters, December 2022, American Chemical Society (ACS)

    Professor Javier Fernández-Ruiz

  23. Endocannabinoid-Binding Receptors as Drug Targets

    Article • September 2022, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  24. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Article • Biomolecules, August 2022, MDPI AG

    Professor Javier Fernández-Ruiz

  25. Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

    Article • Neuropharmacology, March 2022, Elsevier

    Professor Javier Fernández-Ruiz

  26. Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis

    Article • Molecules, December 2021, MDPI AG

    Professor Javier Fernández-Ruiz

  27. BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

    Article • International Journal of Molecular Sciences, November 2021, MDPI AG

    Professor Javier Fernández-Ruiz

  28. (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice

    Article • Pharmacological Research, July 2021, Elsevier

    Professor Javier Fernández-Ruiz

  29. Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease

    Article • Molecules, May 2021, MDPI AG

    Professor Javier Fernández-Ruiz

  30. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Article • Acta Neuropathologica Communications, May 2021, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  31. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

    Article • Brain Pathology, May 2021, Wiley

    Professor Javier Fernández-Ruiz

  32. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    Article • European Journal of Pharmacology, March 2021, Elsevier

    Professor Javier Fernández-Ruiz

  33. Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

    Article • British Journal of Pharmacology, February 2021, Wiley

    Professor Javier Fernández-Ruiz

  34. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    Article • British Journal of Pharmacology, February 2021, Wiley

    Professor Javier Fernández-Ruiz

  35. Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments

    Article • Frontiers in Molecular Neuroscience, January 2021, Frontiers

    Professor Javier Fernández-Ruiz

  36. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice

    Article • Molecular and Cellular Neuroscience, January 2021, Elsevier

    Professor Javier Fernández-Ruiz

  37. Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor**

    Article • Chemistry - A European Journal, November 2020, Wiley

    Professor Javier Fernández-Ruiz

  38. Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors

    Article • British Journal of Pharmacology, July 2020, Wiley

    Professor Javier Fernández-Ruiz

  39. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

    Article • Neurobiology of Disease, July 2020, Elsevier

    Professor Javier Fernández-Ruiz

  40. Possible therapeutic applications of cannabis in the neuropsychopharmacology field

    Article • European Neuropsychopharmacology, July 2020, Elsevier

    Professor Javier Fernández-Ruiz

  41. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

    Article • Scientific Reports, March 2020, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  42. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders

    Article • Biomolecules, February 2020, MDPI AG

    Professor Javier Fernández-Ruiz

  43. Chapter 2. Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System

    Article • January 2020, Royal Society of Chemistry

    Professor Javier Fernández-Ruiz

  44. Structure–Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives

    Article • Frontiers in Pharmacology, November 2019, Frontiers

    Professor Javier Fernández-Ruiz

  45. Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease

    Article • Molecules, July 2019, MDPI AG

    Professor Javier Fernández-Ruiz

  46. Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets

    Article • Frontiers in Molecular Neuroscience, April 2019, Frontiers

    Professor Javier Fernández-Ruiz

  47. Morphine self-administration alters the expression of translational machinery genes in the amygdala of male Lewis rats

    Article • Journal of Psychopharmacology, March 2019, SAGE Publications

    Professor Javier Fernández-Ruiz

  48. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Article • Biochemical Pharmacology, November 2018, Elsevier

    Professor Javier Fernández-Ruiz

  49. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis

    Article • Biochemical Pharmacology, November 2018, Elsevier

    Professor Javier Fernández-Ruiz

  50. Preface: Why a Special Issue on cannabinoid research in Spain?

    Article • Biochemical Pharmacology, November 2018, Elsevier

    Professor Javier Fernández-Ruiz

  51. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways

    Article • British Journal of Pharmacology, August 2018, Wiley

    Professor Javier Fernández-Ruiz

  52. The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes

    Article • British Journal of Pharmacology, July 2018, Wiley

    Professor Javier Fernández-Ruiz

  53. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

    Article • British Journal of Pharmacology, May 2018, Wiley

    Professor Javier Fernández-Ruiz

  54. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

    Article • Journal of Neuroinflammation, January 2018, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  55. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients

    Article • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, January 2018, Taylor & Francis

    Professor Javier Fernández-Ruiz

  56. Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists

    Article • Bioorganic & Medicinal Chemistry, January 2018, Elsevier

    Professor Javier Fernández-Ruiz

  57. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. 110 (August 2016) (2016) 205–215]

    Article • Pharmacological Research, June 2017, Elsevier

    Professor Javier Fernández-Ruiz

  58. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

    Article • PLOS One, April 2017, PLOS

    Professor Javier Fernández-Ruiz

  59. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease

    Article • International Journal of Molecular Sciences, March 2017, MDPI AG

    Professor Javier Fernández-Ruiz

  60. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking

    Article • European Journal of Medicinal Chemistry, February 2017, Elsevier

    Dr. Nadine jagerovic, Professor Javier Fernández-Ruiz

  61. Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione

    Article • Journal of Porphyrins and Phthalocyanines, January 2017, World Scientific Pub Co Pte Lt

    Dr. Nadine jagerovic, Professor Javier Fernández-Ruiz

  62. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Article • January 2017, Elsevier

    Professor Javier Fernández-Ruiz

  63. Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis

    Article • Disease Models & Mechanisms, January 2017, The Company of Biologists

    Professor Javier Fernández-Ruiz

  64. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

    Article • Neuroscience, December 2016, Elsevier

    Professor Javier Fernández-Ruiz

  65. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders

    Article • Frontiers in Neuroscience, September 2016, Frontiers

    Dr. Nadine jagerovic, Professor Javier Fernández-Ruiz

  66. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Article • Pharmacological Research, August 2016, Elsevier

    Professor Javier Fernández-Ruiz

  67. Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

    Article • Pharmacological Research, August 2016, Elsevier

    Professor Javier Fernández-Ruiz

  68. VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease

    Article • Scientific Reports, July 2016, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  69. Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis

    Article • Journal of Medicinal Chemistry, July 2016, American Chemical Society (ACS)

    Professor Javier Fernández-Ruiz

  70. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Article • Journal of Neurology, May 2016, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  71. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties

    Article • European Journal of Medicinal Chemistry, April 2016, Elsevier

    Professor Javier Fernández-Ruiz

  72. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome

    Article • Pharmacology Research & Perspectives, March 2016, Wiley

    Professor Javier Fernández-Ruiz

  73. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways

    Article • Scientific Reports, February 2016, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  74. Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology

    Article • Journal of Medicinal Chemistry, February 2016, American Chemical Society (ACS)

    Professor Javier Fernández-Ruiz

  75. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 2016, Elsevier

    Professor Javier Fernández-Ruiz

  76. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ-tetrahydrocannabinol acting through CB1 receptors

    Article • Multiple Sclerosis and Related Disorders, November 2015, Elsevier

    Professor Javier Fernández-Ruiz

  77. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications

    Article • Neurotherapeutics, August 2015, Springer Science + Business Media

    Prof Maria Angeles Moro, Professor Javier Fernández-Ruiz

  78. Altered CB1receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects

    Article • Journal of Psychopharmacology, August 2015, SAGE Publications

    Professor Javier Fernández-Ruiz

  79. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB 2 receptor antagonists

    Article • European Journal of Medicinal Chemistry, August 2015, Elsevier

    Professor Javier Fernández-Ruiz

  80. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia

    Article • British Journal of Pharmacology, July 2015, Wiley

    Professor Javier Fernández-Ruiz

  81. A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis

    Article • British Journal of Pharmacology, May 2015, Wiley

    Professor Javier Fernández-Ruiz

  82. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

    Article • Journal of Neuroimmune Pharmacology, March 2015, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  83. Selective, Nontoxic CB2Cannabinoido-Quinone with in Vivo Activity against Triple-Negative Breast Cancer

    Article • Journal of Medicinal Chemistry, February 2015, American Chemical Society (ACS)

    Professor Javier Fernández-Ruiz

  84. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease

    Article • Neuroscience Letters, February 2015, Elsevier

    Professor Javier Fernández-Ruiz

  85. Endocannabinoids and Neurodegenerative Disorders: Parkinson’s Disease, Huntington’s Chorea, Alzheimer’s Disease, and Others

    Article • January 2015, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  86. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice

    Article • Neurobiology of Aging, December 2014, Elsevier

    Guy Bormans, Professor Javier Fernández-Ruiz

  87. Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling

    Article • Journal of Biological Chemistry, August 2014, Elsevier

    Professor Javier Fernández-Ruiz

  88. The endocannabinoid system is altered in the post‐mortem prefrontal cortex of alcoholic subjects

    Article • Addiction Biology, July 2014, Wiley

    Dr Luis F Callado, Professor Javier Fernández-Ruiz, Stephen Alexander

  89. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

    Article • Epilepsia, May 2014, Wiley

    Professor Javier Fernández-Ruiz

  90. A restricted population of CB 1 cannabinoid receptors with neuroprotective activity

    Article • Proceedings of the National Academy of Sciences, May 2014, Proceedings of the National Academy of Sciences

    Professor Javier Fernández-Ruiz

  91. Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1G93ATransgenic Mice and Evaluation of a Sativex®-like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis

    Article • CNS Neuroscience & Therapeutics, April 2014, Wiley

    Professor Javier Fernández-Ruiz

  92. Changes in CB1 and CB2 receptors in the post‐mortem cerebellum of humans affected by spinocerebellar ataxias

    Article • British Journal of Pharmacology, March 2014, Wiley

    Professor Javier Fernández-Ruiz

  93. Compounds combining pharmacophoric elements of CB1 and opioid mu.

    Article • Drug Design Development and Therapy, February 2014, Taylor & Francis

    Dr Luis F Callado, Dr. Nadine jagerovic, Luis F Callado, Professor Javier Fernández-Ruiz

  94. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

    Article • European Journal of Medicinal Chemistry, February 2014, Elsevier

    Professor Javier Fernández-Ruiz

  95. Endocannabinoid-Hydrolysing Enzymes in the Post-Mortem Cerebellum of Humans Affected by Hereditary Autosomal Dominant Ataxias

    Article • Pathobiology, January 2014, Karger Publishers

    Professor Javier Fernández-Ruiz

  96. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors

    Article • Neuropharmacology, December 2013, Elsevier

    Professor Javier Fernández-Ruiz

  97. Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity

    Article • European Journal of Medicinal Chemistry, December 2013, Elsevier

    Professor Javier Fernández-Ruiz

  98. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG

    Article • Cell Death and Disease, October 2013, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  99. Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease

    Article • CNS & Neurological Disorders - Drug Targets, July 2013, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  100. Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy

    Article • Journal of Alzheimer’s Disease, May 2013, SAGE Publications

    Professor Javier Fernández-Ruiz

  101. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors

    Article • Multiple Sclerosis Journal, April 2013, SAGE Publications

    Professor Javier Fernández-Ruiz

  102. Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

    Article • Bioorganic & Medicinal Chemistry, April 2013, Elsevier

    Professor Javier Fernández-Ruiz

  103. Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties

    Article • Archiv der Pharmazie, February 2013, Wiley

    Dr Luis F Callado, Dr Francisco Javier Bermudez-Silva, Dr. Nadine jagerovic, Professor Javier Fernández-Ruiz

  104. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

    Article • British Journal of Clinical Pharmacology, January 2013, Wiley

    Professor Javier Fernández-Ruiz

  105. Design and Synthesis of Novel Cannabinoid Ligands Based on a 1,2,3- triazole Scaffold

    Article • Letters in Drug Design & Discovery, December 2012, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  106. Cannabidiol administration after hypoxia–ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function

    Article • Neuropharmacology, October 2012, Elsevier

    Professor Javier Fernández-Ruiz

  107. A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis

    Article • Journal of Neuroimmune Pharmacology, September 2012, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  108. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

    Article • Neuropharmacology, June 2012, Elsevier

    Professor Javier Fernández-Ruiz

  109. Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease

    Article • Recent Patents on CNS Drug Discovery, April 2012, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  110. Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors

    Article • ACS Chemical Neuroscience, March 2012, American Chemical Society (ACS)

    Professor Javier Fernández-Ruiz

  111. Chromenopyrazoles: Non-psychoactive and Selective CB1Cannabinoid Agonists with Peripheral Antinociceptive Properties

    Article • ChemMedChem, February 2012, Wiley

    Dr. Nadine jagerovic, Professor Javier Fernández-Ruiz

  112. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases

    Article • Neuroscience Letters, February 2012, Elsevier

    Professor Javier Fernández-Ruiz

  113. Fármacos cannabinoides para las enfermedades neurológicas: ¿qué hay detrás?

    Article • Revista de Neurología, January 2012, IMR Press

    Professor Javier Fernández-Ruiz

  114. Pharmacological Activation/Inhibition of the Cannabinoid System Affects Alcohol Withdrawal-Induced Neuronal Hypersensitivity to Excitotoxic Insults

    Article • PLOS One, August 2011, PLOS

    Professor Javier Fernández-Ruiz

  115. Prospects for cannabinoid therapies in basal ganglia disorders

    Article • British Journal of Pharmacology, July 2011, Wiley

    Professor Javier Fernández-Ruiz

  116. Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's disease

    Article • British Journal of Pharmacology, July 2011, Wiley

    Professor Javier Fernández-Ruiz

  117. Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism

    Article • Antioxidants & Redox Signaling, June 2011, Mary Ann Liebert Inc

    Professor Javier Fernández-Ruiz

  118. Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease

    Article • Journal of Neuroscience Research, June 2011, Wiley

    Professor Javier Fernández-Ruiz

  119. Reply: Reliability of immunolabelling in the determination of Huntington's disease neuropathy

    Article • Brain, May 2011, Oxford University Press (OUP)

    Professor Javier Fernández-Ruiz

  120. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease

    Article • Brain, October 2010, Oxford University Press (OUP)

    Professor Javier Fernández-Ruiz

  121. A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice

    Article • PLOS One, July 2010, PLOS

    Professor Javier Fernández-Ruiz

  122. Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders

    Article • CNS Neuroscience & Therapeutics, May 2010, Wiley

    Professor Javier Fernández-Ruiz

  123. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain

    Article • European Journal of Neuroscience, April 2010, Wiley

    Professor Javier Fernández-Ruiz

  124. The endocannabinoid system as a target for the treatment of neuronal damage

    Article • Expert Opinion on Therapeutic Targets, March 2010, Informa Healthcare

    Professor Javier Fernández-Ruiz

  125. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors

    Article • Neurobiology of Disease, February 2010, Elsevier

    Professor Javier Fernández-Ruiz

  126. Cannabinoids and Parkinsons Disease

    Article • CNS & Neurological Disorders - Drug Targets, December 2009, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  127. Cannabinoids, multiple sclerosis and neuroprotection

    Article • Expert Review of Clinical Pharmacology, November 2009, Taylor & Francis

    Professor Javier Fernández-Ruiz

  128. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Article • Brain, October 2009, Oxford University Press (OUP)

    Professor Javier Fernández-Ruiz

  129. Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration

    Article • PLOS One, June 2009, PLOS

    Professor Javier Fernández-Ruiz

  130. The endocannabinoid system as a target for the treatment of motor dysfunction

    Article • British Journal of Pharmacology, March 2009, Wiley

    Professor Javier Fernández-Ruiz

  131. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas

    Article • Drug and Alcohol Dependence, January 2009, Elsevier

    Professor Javier Fernández-Ruiz

  132. The endocannabinoid system in neuropathological states

    Article • International Review of Psychiatry, January 2009, Taylor & Francis

    Professor Javier Fernández-Ruiz

  133. Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

    Article • Glia, December 2008, Wiley

    Professor Javier Fernández-Ruiz

  134. Cannabinoid signaling system

    Article • Cell Adhesion & Migration, October 2008, Taylor & Francis

    Professor Javier Fernández-Ruiz

  135. The Endocannabinoid System in Huntingtons Disease

    Article • Current Pharmaceutical Design, August 2008, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  136. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats

    Article • Neuroscience Letters, June 2008, Elsevier

    Professor Javier Fernández-Ruiz

  137. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats

    Article • Neuropharmacology, May 2008, Elsevier

    Professor Javier Fernández-Ruiz

  138. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance

    Article • Neuroscience, May 2008, Elsevier

    Professor Javier Fernández-Ruiz

  139. Role of CB2 receptors in neuroprotective effects of cannabinoids

    Article • Molecular and Cellular Endocrinology, April 2008, Elsevier

    Professor Javier Fernández-Ruiz

  140. Cannabinoid CB1 Receptors Are Expressed by Parietal Cells of the Human Gastric Mucosa

    Article • Journal of Histochemistry & Cytochemistry, February 2008, SAGE Publications

    Professor Javier Fernández-Ruiz

  141. Cannabinoids and Neuroprotection in Motor-Related Disorders

    Article • CNS & Neurological Disorders - Drug Targets, December 2007, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  142. Preface: Cannabinoids as New Tools for the Treatment of Neurological Disorders

    Article • Molecular Neurobiology, August 2007, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  143. Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acidin vivoby mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2Areceptors

    Article • European Journal of Neuroscience, August 2007, Wiley

    Professor Javier Fernández-Ruiz

  144. Cannabinoids and Neuroprotection in Basal Ganglia Disorders

    Article • Molecular Neurobiology, June 2007, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  145. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol

    Article • Neuroscience Letters, June 2007, Elsevier

    Professor Javier Fernández-Ruiz

  146. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain

    Article • Brain Research, May 2007, Elsevier

    Professor Javier Fernández-Ruiz

  147. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties

    Article • Brain Research, February 2007, Elsevier

    Professor Javier Fernández-Ruiz

  148. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions

    Article • Life Sciences, February 2007, Elsevier

    Professor Javier Fernández-Ruiz

  149. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

    Article • Trends in Pharmacological Sciences, January 2007, Elsevier

    Professor Javier Fernández-Ruiz

  150. An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments

    Article • Current Medicinal Chemistry, December 2006, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  151. Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1‐mediated calcium responses in adult DRG neurons; the role of CB1 receptors

    Article • European Journal of Neuroscience, December 2006, Wiley

    Professor Javier Fernández-Ruiz

  152. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice

    Article • European Journal of Neuroscience, October 2006, Wiley

    Professor Javier Fernández-Ruiz

  153. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice

    Article • Brain Research, August 2006, Elsevier

    Professor Javier Fernández-Ruiz

  154. Acyl‐based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations

    Article • Journal of Neurochemistry, July 2006, Wiley

    Professor Javier Fernández-Ruiz

  155. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease

    Article • Brain Research, February 2006, Elsevier

    Professor Javier Fernández-Ruiz

  156. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders

    Article • European Neuropsychopharmacology, January 2006, Elsevier

    Professor Javier Fernández-Ruiz

  157. Chronic Δ9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, December 2005, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  158. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

    Article • Neurobiology of Disease, November 2005, Elsevier

    Professor Javier Fernández-Ruiz

  159. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels

    Article • Biochemical Pharmacology, August 2005, Elsevier

    Professor Javier Fernández-Ruiz

  160. Therapeutic Potential of the Endocannabinoid System in the Brain

    Article • Mini-Reviews in Medicinal Chemistry, July 2005, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  161. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease

    Article • Brain Research, July 2005, Elsevier

    Professor Javier Fernández-Ruiz

  162. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice

    Article • Brain Research, June 2005, Elsevier

    Professor Javier Fernández-Ruiz

  163. Cannabinoid tolerance and dependence: A review of studies in laboratory animals

    Article • Pharmacology Biochemistry and Behavior, June 2005, Elsevier

    Professor Javier Fernández-Ruiz

  164. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

    Article • Neurobiology of Disease, June 2005, Elsevier

    Professor Javier Fernández-Ruiz

  165. Article • Pharmacology Biochemistry and Behavior, June 2005, Elsevier

    Professor Javier Fernández-Ruiz

  166. Changes in endocannabinoid contents in reward‐related brain regions of alcohol‐exposed rats, and their possible relevance to alcohol relapse

    Article • British Journal of Pharmacology, October 2004, Wiley

    Professor Javier Fernández-Ruiz

  167. Effects of Neonatal Exposure to Methamphetamine: Catecholamine Levels in Brain Areas of the Developing Rat

    Article • Annals of the New York Academy of Sciences, October 2004, Wiley

    Professor Javier Fernández-Ruiz

  168. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo

    Article • Neuroreport, October 2004, Wolters Kluwer Health

    Professor Javier Fernández-Ruiz

  169. Involvement of the Endocannabinoid System in Motor Disorders

    Article • Current Medicinal Chemistry - Central Nervous System Agents, September 2004, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  170. Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal Δ9-tetrahydrocannabinol exposure

    Article • The Cerebellum, June 2004, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  171. Behavioral and molecular changes elicited by acute administration of SR141716 to Δ9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence

    Article • Drug and Alcohol Dependence, May 2004, Elsevier

    Professor Javier Fernández-Ruiz

  172. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence

    Article • Brain Research, May 2004, Elsevier

    Professor Javier Fernández-Ruiz

  173. Transthyretin is involved in depression‐like behaviour and exploratory activity

    Article • Journal of Neurochemistry, February 2004, Wiley

    Professor Javier Fernández-Ruiz

  174. Cannabinoids and gene expression during brain development

    Article • Neurotoxicity Research, January 2004, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  175. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake

    Article • European Journal of Pharmacology, January 2004, Elsevier

    Professor Javier Fernández-Ruiz

  176. Prenatal Cannabinoid Exposure Down- Regulates Glutamate Transporter Expressions (GLAST and EAAC1) in the Rat Cerebellum

    Article • Developmental Neuroscience, January 2004, Karger Publishers

    Professor Javier Fernández-Ruiz

  177. Prenatal cannabinoid exposure and gene expression for neural adhesion molecule L1 in the fetal rat brain

    Article • Developmental Brain Research, December 2003, Elsevier

    Professor Javier Fernández-Ruiz

  178. The Endocannabinoid System and Huntingtons Disease

    Article • Current Drug Targets - CNS & Neurological Disorders, October 2003, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  179. Effects of perinatal exposure to Δ9-tetrahydrocannabinol on operant morphine-reinforced behavior

    Article • Pharmacology Biochemistry and Behavior, June 2003, Elsevier

    Professor Javier Fernández-Ruiz

  180. Region‐dependent changes in endocannabinoid transmission in the brain of morphine‐dependent rats

    Article • Addiction Biology, June 2003, Wiley

    Professor Javier Fernández-Ruiz

  181. Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate

    Article • Neuroreport, May 2003, Wolters Kluwer Health

    Professor Javier Fernández-Ruiz

  182. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors

    Article • European Journal of Medicinal Chemistry, April 2003, Elsevier

    Professor Javier Fernández-Ruiz

  183. Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake:  Comparison with Effects on Fatty Acid Amidohydrolase

    Article • Journal of Medicinal Chemistry, March 2003, American Chemical Society (ACS)

    Professor Javier Fernández-Ruiz

  184. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

    Article • Journal of Neurochemistry, February 2003, Wiley

    Professor Javier Fernández-Ruiz

  185. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine

    Article • Brain Research, November 2002, Elsevier

    Professor Javier Fernández-Ruiz

  186. The endogenous cannabinoid system and the basal ganglia

    Article • Pharmacology & Therapeutics, August 2002, Elsevier

    Professor Javier Fernández-Ruiz

  187. Erratum to “The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats” [Life Sciences 70(12) (2002) 1407-1414]

    Article • Life Sciences, August 2002, Elsevier

    Professor Javier Fernández-Ruiz

  188. PREFACE

    Article • Pharmacology & Therapeutics, August 2002, Elsevier

    Professor Javier Fernández-Ruiz

  189. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide

    Article • European Journal of Pharmacology, August 2002, Elsevier

    Professor Javier Fernández-Ruiz

  190. Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA‐induced excitotoxicity

    Article • Journal of Neurochemistry, June 2002, Wiley

    Professor Javier Fernández-Ruiz

  191. Endocannabinoid Transporter Inhibitors

    Article • Current Medicinal Chemistry - Central Nervous System Agents, June 2002, Bentham Science Publishers

    Professor Javier Fernández-Ruiz

  192. Prenatal Exposure to Methamphetamine in the Rat

    Article • Annals of the New York Academy of Sciences, June 2002, Wiley

    Professor Javier Fernández-Ruiz

  193. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels

    Article • Drug and Alcohol Dependence, March 2002, Elsevier

    Professor Javier Fernández-Ruiz

  194. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington’s disease

    Article • Brain Research, March 2002, Elsevier

    Professor Javier Fernández-Ruiz

  195. Endocannabinoids and basal ganglia functionality

    Article • Prostaglandins Leukotrienes and Essential Fatty Acids, February 2002, Elsevier

    Professor Javier Fernández-Ruiz

  196. The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats

    Article • Life Sciences, February 2002, Elsevier

    Professor Javier Fernández-Ruiz

  197. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

    Article • Synapse, January 2002, Wiley

    Professor Javier Fernández-Ruiz

  198. Exposure to cannabinoids in the development of endogenous cannabinoid system

    Article • Neurotoxicity Research, January 2002, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  199. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Δ-tetrahydrocannabinol

    Article • Neurotoxicity Research, January 2002, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  200. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease

    Article • Neurotoxicity Research, January 2002, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  201. Reduced Glial Fibrillary Acidic Protein and Glutamine Synthetase Expression in Astrocytes and Bergmann Glial Cells in the Rat Cerebellum Caused by Δ<sup>9</sup>-Tetrahydrocannabinol Administration during Development

    Article • Developmental Neuroscience, January 2002, Karger Publishers

    Professor Javier Fernández-Ruiz

  202. Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets

    Article • European Journal of Neuroscience, December 2001, Wiley

    Professor Javier Fernández-Ruiz

  203. Design, Synthesis and Biological Evaluation of Novel Arachidonic Acid Derivatives as Highly Potent and Selective Endocannabinoid Transporter Inhibitors

    Article • Journal of Medicinal Chemistry, November 2001, American Chemical Society (ACS)

    Professor Javier Fernández-Ruiz

  204. Effects of cannabinoids on adrenaline release from adrenal medullary cells

    Article • British Journal of Pharmacology, November 2001, Wiley

    Professor Javier Fernández-Ruiz

  205. Anandamide, but not 2‐arachidonoylglycerol, accumulates during in vivo neurodegeneration

    Article • Journal of Neurochemistry, September 2001, Wiley

    Professor Javier Fernández-Ruiz

  206. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease

    Article • Neuroreport, July 2001, Wolters Kluwer Health

    Professor Javier Fernández-Ruiz

  207. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis

    Article • Synapse, May 2001, Wiley

    Professor Javier Fernández-Ruiz

  208. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues

    Article • European Journal of Pharmacology, May 2001, Elsevier

    Professor Javier Fernández-Ruiz

  209. Decreased Cannabinoid CB1 Receptor mRNA Levels and Immunoreactivity in Pituitary Tumors Induced by Prolonged Exposure to Estrogens

    Article • Pituitary, December 2000, Springer Science + Business Media

    Professor Javier Fernández-Ruiz

  210. Neonatal Methamphetamine in the Rat: Evidence for Gender‐specific Differences upon Tyrosine Hydroxylase Enzyme in the Dopaminergic Nigrostriatal System

    Article • Annals of the New York Academy of Sciences, September 2000, Wiley

    Professor Javier Fernández-Ruiz

  211. Uso de los cannabinoides a través de la historia

    Article • Adicciones, June 2000, Socidrogalcohol

    Professor Javier Fernández-Ruiz

  212. Sistema cannabinoide endógeno: ligandos y receptores acoplados a mecanismos de transducción de señales

    Article • Adicciones, June 2000, Socidrogalcohol

    Professor Javier Fernández-Ruiz

  213. Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9‐Tetrahydrocannabinol‐Tolerant Rats

    Article • Journal of Neurochemistry, April 2000, Wiley

    Professor Javier Fernández-Ruiz

  214. Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland

    Article • Biochemical and Biophysical Research Communications, April 2000, Elsevier

    Professor Javier Fernández-Ruiz

  215. Activational role of cannabinoids on movement

    Article • European Journal of Pharmacology, March 2000, Elsevier

    Professor Javier Fernández-Ruiz

  216. Prenatal Δ9-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences

    Article • Developmental Brain Research, March 2000, Elsevier

    Professor Javier Fernández-Ruiz

  217. Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme

    Article • Brain Research, February 2000, Elsevier

    Professor Javier Fernández-Ruiz

  218. Neuronal and Astroglial Response to Pre- and Perinatal Exposure to Delta-9-Tetra- Hydrocannabinol in the Rat Substantia nigra

    Article • Developmental Neuroscience, January 2000, Karger Publishers

    Professor Javier Fernández-Ruiz

  219. The endogenous cannabinoid system and brain development

    Article • Trends in Neurosciences, January 2000, Elsevier

    Professor Javier Fernández-Ruiz

  220. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen

    Article • Life Sciences, January 2000, Elsevier

    Professor Javier Fernández-Ruiz

  221. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period

    Article • Synapse, September 1999, Wiley

    Professor Javier Fernández-Ruiz

  222. Pharmacological and biochemical interactions between opioids and cannabinoids

    Article • Trends in Pharmacological Sciences, July 1999, Elsevier

    Professor Javier Fernández-Ruiz

  223. Role of endocannabinoids in brain development

    Article • Life Sciences, July 1999, Elsevier

    Professor Javier Fernández-Ruiz

  224. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPγS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide

    Article • Neurochemistry International, June 1999, Elsevier

    Professor Javier Fernández-Ruiz

  225. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to Δ9-tetrahydrocannabinol

    Article • Drug and Alcohol Dependence, June 1999, Elsevier

    Professor Javier Fernández-Ruiz

  226. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide

    Article • Life Sciences, June 1999, Elsevier

    Professor Javier Fernández-Ruiz

  227. Perinatal Δ9-Tetrahydrocannabinol Exposure Augmented the Magnitude of Motor Inhibition Caused by GABAB, but not GABAA, Receptor Agonists in Adult Rats

    Article • Neurotoxicology and Teratology, May 1999, Elsevier

    Professor Javier Fernández-Ruiz

  228. Time-dependent differences of repeated administration with Δ9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by μ-opioid and CB1-cannabinoid receptors in the caudate–putamen

    Article • Molecular Brain Research, April 1999, Elsevier

    Professor Javier Fernández-Ruiz

  229. Identification of Endocannabinoids and Cannabinoid CB<sub>1</sub> Receptor mRNA in the Pituitary Gland

    Article • Neuroendocrinology, January 1999, Karger Publishers

    Professor Javier Fernández-Ruiz